Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in positive and negative syndrome scale (PANSS) […]

Therapeutic Solutions International (TSOI) has announced that its spin-off biotech company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva-based system.  Previously, the company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker. In the trial, the company previously assessed levels of the inflammatory marker in 10 […]